Archive


Category: Calithera

  • PharmaShots Weekly Snapshots (October 18 – 22, 2021)

    LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis Published: 22 Oct, 2021 | Tags: LEO, Tralokinumab, P-III, ECZTRA 6 Trial, Atopic Dermatitis Marinomed Biotech Signs a License Agreement with Luoxin to Commercialize Budesolv (budesonide nasal spray) in Greater China Published: 22 Oct, 2021 | Tags: […]

  • Takeda Signs an Agreement with Calithera to Acquire Sapanisertib and Mivavotinib

    Shots: Takeda is eligible to receive $10M up front in addition to $35M in Calithera Series A preferred stock and is eligible to receive clinical development, regulatory, and sales milestone for both programs along with royalties The acquisition will bolster Calithera’s precision oncology pipeline of clinical-stage targeted therapies i.e., sapanisertib (TORC 1/2 inhibitor) and mivavotinib […]

  • Top 20 Biopharma Deal Terminations of 2020 Based on Total Deal Value

    The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. Sanofi and Hanmi’s agreement in 2015 ranked first under which Hanmi regained WW rights to its protein/peptide discovery technology, lapscovery. The second position goes to the […]